scholarly journals sidebar: Prescription Drug Diversion: A Law Enforcement Perspective

2013 ◽  
Vol 74 (3) ◽  
pp. 246-246
Author(s):  
Donnie R. Varnell
2019 ◽  
Author(s):  
Buyisile Chibi ◽  
Tivani P Mashamba-Thompson

Abstract Background: Prescription drug diversion, misuse and abuse is a growing health threat negatively impacting the health care system and individuals globally. Most research has been conducted in high-income-countries. Little is known about prescription drug diversion, misuse and abuse to support anecdotal reports in resource-limited settings. Purpose: The main objective of this study is to determine prescription drug diversion, misuse and abuse practices in eThekwini district from the perspective of the health care providers, law enforcement, pharmacists, drug users and people living with HIV. Methods: Semi-structured in-depth-interviews were conducted between June-December 2018 among key stakeholders who were purposively sampled in eThekwini district. Thematic analysis was used to identify emergent themes around practices of prescription drug diversion, misuse and abuse. Results: Five main themes emerged during the interviews: manifestation of drug diversion; consumer’s attitude and behaviour; availability of medicines; gaps in the health care system; and lastly challenges and barriers to drug abuse treatment. Accidental addiction, health system gaps and consumer’s attitude and behaviours were perceived as significant contributing factors to the problem therefore negatively impacting health care providers and consumers. Conclusion: The study highlights the emerging practices of prescription drug diversion, misuse and abuse as a serious growing problem occurring through legal and illegal channels to anyone since the addictive medicines are readily available and easily accessible. We recommend a collaborative approach to address prescription drug diversion since the prescriber, dispenser, consumer and law enforcement are involved in the cycle to drug usage.


1993 ◽  
Author(s):  
Constance Horgan ◽  
◽  
Jeffrey Prottas ◽  
Christopher Tompkins ◽  
Linda Wastila ◽  
...  

JAMA ◽  
1992 ◽  
Vol 268 (10) ◽  
pp. 1306-1310 ◽  
Author(s):  
J. R. Cooper

Author(s):  
John J. Coleman

This chapter discusses how the pharmaceutical industry’s actions affected the accomplishments of the Decade of Pain Control and Research, which began on January 1, 2001, following almost two decades of rising concern over the inadequate treatment of chronic pain in the United States. To tell the story of this decade we must describe the accompanying problem of drug diversion and abuse. The development in 1995 of a new opioid product called OxyContin, its aggressive marketing, the morbidity and mortality associated with its misuse, and the eventual felony conviction in 2007 of the drug’s sponsor for fraudulent claims and marketing practices, affected the Decade in unexpected ways. The response by Congress and the regulatory community to what they termed an “epidemic” of prescription drug abuse produced long-lasting policy changes. The chapter also touches on the peculiar and sometimes troubling relationship between the regulators and the regulated.


2009 ◽  
Vol 28 (4) ◽  
pp. 332-347 ◽  
Author(s):  
James A. Inciardi ◽  
Hilary L. Surratt ◽  
Theodore J. Cicero ◽  
Steven P. Kurtz ◽  
Steven S. Martin ◽  
...  

2013 ◽  
Vol 23 (2) ◽  
pp. 123-128 ◽  
Author(s):  
Lisa J. Merlo ◽  
Simone M. Cummings ◽  
Linda B. Cottler

Pain Medicine ◽  
2007 ◽  
Vol 8 (2) ◽  
pp. 171-183 ◽  
Author(s):  
James A. Inciardi ◽  
Hilary L. Surratt ◽  
Steven P. Kurtz ◽  
Theodore J. Cicero

Sign in / Sign up

Export Citation Format

Share Document